Michael E. Sneed net worth and biography

Michael Sneed Biography and Net Worth

Michael Sneed is Executive Vice President, Global Corporate Affairs & Chief Communication Officer, and a member of the Executive Committee. He was appointed to the Executive Committee in 2018. Since 2012 he has been leading the Corporation’s global marketing, communication, design and philanthropy functions. Prior to that, he was Company Group Chairman for Johnson & Johnson and a member of the Medical Devices & Diagnostics Group Operating Committee, a role he assumed in January 2007. He had primary responsibility for the global vision care franchise.

Michael joined Johnson & Johnson in 1983 as a Marketing Assistant for Personal Products Company. He held positions of increasing responsibility in the marketing organization. In 1991, he moved to McNeil Consumer Products as a Group Product Director and was promoted to Vice President, Worldwide Consumer Pharmaceuticals in 1995 to lead the company’s growth in the Asia Pacific, Eastern European and Latin American regions.

In 1998 Michael relocated to Europe as Managing Director, McNeil Consumer Nutritionals Europe. He returned to the U.S. as President, McNeil Nutritionals Worldwide, in 2000. In 2002, he was named Global President, Personal Products Company. Michael was promoted to Company Group Chairman and a member of the Consumer and Personal Care Group Operating Committee in 2004, with North American responsibility for the Personal Products Company, Johnson & Johnson Sales and Logistics Company and Johnson & Johnson Consumer Canada. In his role, he also had North American responsibility for the IT, Finance and HR organizations within the Consumer & Personal Care group.

Michael is a member of the Board of Trustees at Macalester College and the Thomas Jefferson Health System. He is a member of the Board of Directors of Wayfair, and also serves on the Executive Committee of the Ad Council. Michael holds a Master’s degree in business administration from the Tuck School of Business at Dartmouth College and a Bachelor of Arts degree, cum laude, from Macalester College.

What is Michael E. Sneed's net worth?

The estimated net worth of Michael E. Sneed is at least $18.22 million as of December 9th, 2020. Mr. Sneed owns 110,741 shares of Johnson & Johnson stock worth more than $18,220,217 as of September 29th. This net worth evaluation does not reflect any other investments that Mr. Sneed may own. Learn More about Michael E. Sneed's net worth.

How do I contact Michael E. Sneed?

The corporate mailing address for Mr. Sneed and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400. Learn More on Michael E. Sneed's contact information.

Has Michael E. Sneed been buying or selling shares of Johnson & Johnson?

Michael E. Sneed has not been actively trading shares of Johnson & Johnson during the last ninety days. Most recently, Michael E. Sneed sold 54,662 shares of the business's stock in a transaction on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a transaction totalling $8,359,459.66. Following the completion of the sale, the chief operating officer now directly owns 110,741 shares of the company's stock, valued at $16,935,621.13. Learn More on Michael E. Sneed's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), Kathryn Wengel (EVP), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 5 times. They sold a total of 106,842 shares worth more than $18,885,128.67. The most recent insider tranaction occured on June, 10th when EVP Kathryn E Wengel sold 40,000 shares worth more than $6,920,000.00. Insiders at Johnson & Johnson own 0.4 % of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 6/10/2022.

Michael E. Sneed Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2020Sell54,662$152.93$8,359,459.66110,741View SEC Filing Icon  
1/30/2020Sell58,128$149.39$8,683,741.92107,511View SEC Filing Icon  
11/23/2018Sell30,943$142.46$4,408,139.7870,817View SEC Filing Icon  
8/27/2018Sell29,000$134.80$3,909,200.0059,124View SEC Filing Icon  
See Full Table

Michael E. Sneed Buying and Selling Activity at Johnson & Johnson

This chart shows Michael E Sneed's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $164.53
Low: $163.89
High: $167.17

50 Day Range

MA: $167.44
Low: $161.33
High: $174.59

2 Week Range

Now: $164.53
Low: $155.72
High: $186.69

Volume

6,987,240 shs

Average Volume

7,524,048 shs

Market Capitalization

$432.58 billion

P/E Ratio

23.95

Dividend Yield

2.72%

Beta

0.61